4.7 Review

Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders - the case of yohimbine

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 31, Issue 1, Pages 2-7

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2009.10.003

Keywords

-

Funding

  1. NIAAA
  2. NIH [MH058883, MH081975]
  3. NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH058883, R29MH058883, R01MH081975, R01MH058883] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000411] Funding Source: NIH RePORTER

Ask authors/readers for more resources

There is current interest in identifying drugs that facilitate fear extinction, as this form of learning is the basis of certain cognitive therapies for anxiety disorders. Following an initial report several years ago that the alpha 2-adrenoreceptor antagonist yohimbine facilitated extinction in mice, more recent studies have shown mixed effects or even impairment. It has become clear that the effect of yohimbine on extinction depends on a number of factors, including genetic background, contextual variables and the presence of competing behaviors. To what extent theses effects of yohimbine are mediated through the alpha 2-adrenoreceptor, as opposed to other sites of action, is also uncertain. More work is needed before this drug can be approved as a pharmacological adjunct for extinction-based therapies. More generally, the case of yohimbine may serve as a model for the development of other extinction facilitators.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available